Showing 3861-3870 of 7247 results for "".
- Landmark Data: Neoadjuvant Pembrolizumab Improves Outcomes for High-risk Melanoma Patientshttps://practicaldermatology.com/news/landmark-data-neoadjuvant-pembrolizumab-improves-outcomes-for-high-risk-melanoma-patients/2461589/Patients with high-risk melanoma who received pembrolizumab both before and after surgery had a significantly lower risk of their cancer recurring than patients who received the drug only after surgery. These results, published today in the
- Candela Announces Health Canada Licences for Nordlys Multi-Application System and Frax Pro Devicehttps://practicaldermatology.com/news/candela-announces-health-canada-licences-for-nordlys-multi-application-system-and-frax-pro-device/2461586/Candela announced Health Canada licensing and the availability of the Nordlys multi-application platform, which features Selective Waveband Technology (SWT) and the dual-wavelength Frax Pro non-ablative fractional laser platform.[1-4] The Nordlys is designed to improve treatme
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an
- Celluma Light Therapy Headquarters Moves to Tustin, Californiahttps://practicaldermatology.com/news/celluma-light-therapy-headquarters-moves-to-tustin-calif/2461570/BioPhotas, Inc., the maker of the Celluma Series of light therapy devices, is moving its corporate headquarters and manufacturing operations from Anaheim to Tustin, Calif. The new headquarters boasts 25,000 square feet of office and warehouse space, facilitating continued gro
- Hydrafacial X Omorovicza Collab: Advanced Skin Renewal Boosterhttps://practicaldermatology.com/news/hydrafacial-x-omorovicza-collab-advanced-skin-renewal-booster/2461569/The Beauty Health Company’s Hydrafacial is rolling out a new booster co-created with Hungarian skincare brand Omorovicza. The booster, available immediately to Hydrafacial providers in North America and EMEA, leverages Omorovicza’s patented Healing Concentrate for a mo
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- DermTech Melanoma Test Recommended for Coverage by the Veterans Health Administrationhttps://practicaldermatology.com/news/dermtech-melanoma-test-recommended-for-coverage-by-the-veterans-health-administration/2461554/The U.S. General Services Administration has recommended DermTech‘s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA), according to a company news release. This coverage recommendation makes the foundational as
- Medical Groups Offer Updated Guidance on Hand Hygiene in Healthcare Settingshttps://practicaldermatology.com/news/groups-offer-updated-guidance-on-hand-hygiene-in-healthcare-settings/2461551/Five medical organizations are recommending updated best practices for hand hygiene to protect patients and staff in healthcare settings. The new recommendations emphasize the importance of healthy skin and nails and easy access to alcohol-based hand sanitizers. Strategi